Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07758660

Alzheimer's Disease Research Center (ADRC) PET Component Study

The purpose of this study is to further engage and characterize Alzheimer's Disease Research Center (ADRC) participants through additional research opportunities, particularly PET imaging. Amyloid and Tau PET imaging will be collected in 24 participants per year, for a total of 120 participants over five years.

All participants will be followed longitudinally, including through potential transitions from normal aging to mild cognitive impairment (MCI) and Alzheimer's disease and related dementias (ADRD).

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Alzheimer Disease Brain Diseases Central Nervous System Diseases Cognition Disorders Cognitive Dysfunction Dementia Mental Disorders Mild Cognitive Impairment (MCI) Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Columbia University Irving Medical Center

New York, 10032, United States

About this study

This study is a PET imaging component of the broader Alzheimer's Disease Research Center (ADRC) Clinical Core being conducted at Columbia University Irving Medical Center and is designed to further characterize ADRC participants through amyloid and tau PET imaging. The PET component supports the broader ADRC goals of maintaining a well-characterized, diverse longitudinal cohort across the spectrum of normal aging, mild cognitive impairment (MCI), and Alzheimer's disease and related dementias (ADRD), and facilitating collaborative research on cognitive aging and ADRD.

Participants in this study must first be enrolled in the parent ADRC protocol. Individuals may be approached for participation in the PET component at the time of ADRC enrollment or may be contacted after enrollment to determine their interest in participating.

Participants will complete up to three outpatient visits over a 12-month period. Study procedures include informed consent, Amyloid PET, and Tau PET imaging of the brain. Depending on scheduling and eligibility, informed consent and PET imaging may occur on the same day.

PET imaging data collected through this study will complement the longitudinal clinical and cognitive characterization performed under the parent ADRC protocol. Because ADRC participants are followed longitudinally, PET imaging may help characterize participants across the spectrum of cognitive aging, including potential transitions from normal cognition to MCI and ADRD.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Enrolled in the Alzheimer's Disease Resource Center (ADRC)
  • With or without memory problems or impairment
  • Able to participate in all scheduled evaluations and to complete all required tests and procedures in either English or Spanish.
  • In the opinion of the PI, the participant must be considered likely to comply with the study protocol and to have a high probability of completing the study.

Exclusion criteria

  • Conditions precluding entry into the scanners (e.g., morbid obesity, claustrophobia, etc.)
  • Pregnant and/or breastfeeding
  • In the opinion of the PI, the subject has been determined unlikely to complete all procedures.

Treatment and study plan

18F-MK6240

Drug

MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.

Other names: [18F-MK6240]

18F-Florbetaben (FBB)

Drug

Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. Florbetaben measures amyloid in the brain.

Other names: [18F] Florbetaben

Primary outcomes

  1. 18F-FBB Standardized Uptake Value Ratio

    Time frame: Up to 12 months

    The standardized uptake value ratio is the concentration of radioactivity measured from the 18F-FBB PET scan in the cortex compared to the uptake in the cerebellum (pseudo-reference region).

  2. 18F-MK6240 Standardized Uptake Value Ratio

    Time frame: Up to 12 months

    The standardized uptake value ratio is the concentration of radioactivity measured from the 18F-MK6240 PET scan in the cortex compared to the uptake in the cerebellum (pseudo-reference region).

Sponsors and collaborators

Lead sponsor

Patrick Lao

Other

Collaborators

  • National Institute on Aging (NIA)

Registry information

Official study title

Alzheimer's Disease Research Center PET Component

Acronym: ADRC PET

Important dates

Study start
2026
Primary completion
2031
Study completion
2033
First posted
Aug 11, 2026
Registry last updated
Aug 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.